Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection

Table 1 Demographic characteristics of the patients

		Lafutidinegroup	Lansoprazolegroup	P
No. of patients		20	20	-
Sex (male:female)		13:7	14:6	NS
Mean age (range)		51.1 (22-66)	50.6 (20-79)	NS
Site of ulcer (gastric ulcer:duodenal ulcer)		12:8	10:10	NS
History of ulcer	Initial onset	3	5	NS
	Recurrence	15	14
	Unknown	2	1
Pretreatment within	None	15	13	NS
1 wk before treatment	Done	3	6
	Unknown	2	1
Pretreatment with an H2-receptor antagonist	None	14	14	NS
	Done	6	6
CYP2C19		6:9:1:4	5:8:6:1 P < 0.05
(homoEM : heteroEM:PM:Unknown)
Sensitive or resistant to clarithromycin		16:1:3	15:1:4	NS
Sensitive (MIC < 1) resistant:(MIC ≥ 1):Unknown

HomoEM: homozygous-extensive metabolizer; heteroEM: hetreozygous-extensive metabolizer; PM: poor metabolizer; MIC: minimal inhibitory concentration.